Cargando…

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies

SIMPLE SUMMARY: Epidermal growth factor receptor (EGFR) mutations occur in a significant number of lung cancer patients. Treatment outcomes in this subset of patients has greatly improved over the last decade after the introduction of EGFR tyrosine kinase inhibitors (TKIs), which demonstrated high e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khaddour, Karam, Jonna, Sushma, Deneka, Alexander, Patel, Jyoti D., Abazeed, Mohamed E., Golemis, Erica, Borghaei, Hossein, Boumber, Yanis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267708/ https://www.ncbi.nlm.nih.gov/pubmed/34202748 http://dx.doi.org/10.3390/cancers13133164

Ejemplares similares

Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
por: Deneka, Alexander Y., et al.
Publicado: (2019)

Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)
por: Makhov, Petr, et al.
Publicado: (2021)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Khaddour, Karam, et al.
Publicado: (2020)

Prognostic role and biologic features of Musashi-2 expression in colon polyps and during colorectal cancer progression
por: Kharin, Leonid, et al.
Publicado: (2021)

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer
por: Khaddour, Karam, et al.
Publicado: (2022)

An improved method of delivering a sclerosing agent for the treatment of malignant pleural effusion
por: Beck, Tim N., et al.
Publicado: (2019)

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
por: Arora, Sanjeevani, et al.
Publicado: (2019)

Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)
por: Khabibov, Marsel, et al.
Publicado: (2022)

Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease
por: Nikonova, Anna S., et al.
Publicado: (2015)

How to Treat EGFR-Mutated Non–Small Cell Lung Cancer
por: Belani, Neel, et al.
Publicado: (2023)

Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancer
por: Bychkov, Igor, et al.
Publicado: (2023)

Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer
por: Bychkov, Igor, et al.
Publicado: (2023)

Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
por: Kamel, Josette, et al.
Publicado: (2021)

Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion
por: Patel, Sandip, et al.
Publicado: (2023)

NEDD9 sustains hexokinase expression to promote glycolysis
por: Deneka, Alexander Y., et al.
Publicado: (2022)

Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer
por: Beck, Tim N., et al.
Publicado: (2019)

Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model
por: Deneka, Alexander Y., et al.
Publicado: (2017)

Case Report: The Importance of Novel Coronavirus Disease (COVID-19) and Coinfection with Other Respiratory Pathogens in the Current Pandemic
por: Khaddour, Karam, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma
por: Makinoshima, Hideki, et al.
Publicado: (2014)

Case report: reinitiating pembrolizumab treatment after small bowel perforation
por: Beck, Tim N., et al.
Publicado: (2019)

NSD1 supports cell growth and regulates autophagy in HPV-negative head and neck squamous cell carcinoma
por: Topchu, Iuliia, et al.
Publicado: (2023)

Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer
por: Deneka, Alexander Y., et al.
Publicado: (2020)

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
por: Jorge, S.E.D.C., et al.
Publicado: (2014)

Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
por: Topchu, Iuliia, et al.
Publicado: (2021)

Rationally designed inhibitors of the Musashi protein-RNA interaction by hotspot mimicry
por: Bai, Nan, et al.
Publicado: (2023)

Rationally designed inhibitors of the Musashi protein-RNA interaction by hotspot mimicry
por: Bai, Nan, et al.
Publicado: (2023)

Metachronous cutaneous squamous cell carcinoma in a young patient as the only presenting symptom to uncover Lynch syndrome with MLH1 Germline mutation
por: Khaddour, Karam, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
por: Peraldo-Neia, Caterina, et al.
Publicado: (2011)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer
por: Gini, Beatrice, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
por: O’Leary, Connor, et al.
Publicado: (2020)

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
por: Harrison, Peter T., et al.
Publicado: (2020)

Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
por: Khaddour, Karam, et al.
Publicado: (2021)

Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review
por: Khaddour, Karam, et al.
Publicado: (2019)

Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency
por: Khaddour, Karam, et al.
Publicado: (2021)

Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia
por: Abedi-Ardekani, Behnoush, et al.
Publicado: (2012)

Lack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in China
por: Cao, Wen-Ming, et al.
Publicado: (2015)

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas
por: Magkou, Christina, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_bvsvgvfevnu24mbclqr95fm4kg